<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H6CF4B1DBA7964D99B511AE562BDAFE11" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 326 IH: Neuromyelitis Optica Consortium Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-01-05</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 326</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170105">January 5, 2017</action-date><action-desc><sponsor name-id="L000551">Ms. Lee</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Public Health Service Act to create a National Neuromyelitis Optica Consortium to
			 provide grants and coordinate research with respect to the causes of, and
			 risk factors associated with, neuromyelitis optica, and for other
			 purposes.</official-title></form>
	<legis-body id="H4858200A4FFD47B4A8C32411B28C16B6" style="OLC">
 <section id="H67359AA07B1C41999F451FCF106275DB" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Neuromyelitis Optica Consortium Act</short-title></quote>.</text> </section><section id="H79E6CED617664A978F007BE127185B09"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress finds the following:</text>
 <paragraph id="H0921E85CA7F744B880B55716450847D6"><enum>(1)</enum><text>Neuromyelitis optica (NMO) is a devastating neurologic disease leading to blindness and paralysis.</text> </paragraph><paragraph id="HF99D27FC267243E6B0919D049417992C"><enum>(2)</enum><text>There are an estimated 16,000 to 17,000 people with NMO in the United States and a quarter-million worldwide.</text>
 </paragraph><paragraph id="HD2372D2916C94023809E42CB2668270A"><enum>(3)</enum><text>Women are affected 4 to 5 times more than men, and Afro-Caribbeans are about 2.5 times more predisposed to NMO than Caucasians. The reasons why Blacks are disproportionately affected cannot be fully understood without further studies.</text>
 </paragraph><paragraph id="H4CF8A997724A4F988F0BEC7176F521B8"><enum>(4)</enum><text>The average age at diagnosis is between 40 and 50 years, but the range is broad and includes children as young as 3 years of age and adults as old as 90 years of age.</text>
 </paragraph><paragraph id="H163755ED1EDE49EC83805EAF4EF241C7"><enum>(5)</enum><text>NMO incurs substantial costs for affected patients and their families.</text> </paragraph><paragraph id="H5F44123F6ACF4B6B988BB1D7FE9FFEEC"><enum>(6)</enum><text>The cause of NMO is unknown, but it is hypothesized to be autoimmune in nature.</text>
 </paragraph><paragraph id="H303726BBB5BE41F4AB25C1AA715C139E"><enum>(7)</enum><text>More than 90 percent of NMO patients will suffer recurrent disease and accumulate neurologic disability.</text>
 </paragraph><paragraph id="H0E5380EEC14F4699AF5D39FE44124D49"><enum>(8)</enum><text>Because of their relatively low overall incidence, orphan diseases like NMO frequently do not receive sufficient attention and research funding.</text>
 </paragraph><paragraph id="HE60A6706B4384C6C987F49120D8F282B"><enum>(9)</enum><text>No single institution has a sufficient number of patients to independently conduct research that will adequately address the cause of NMO.</text>
 </paragraph><paragraph id="H9E561D164466421795AC9433A405D3D7"><enum>(10)</enum><text>There has been no comprehensive study analyzing all relevant clinical, biological, and epidemiological aspects of NMO to identify potential risk factors and biomarkers for NMO.</text>
 </paragraph><paragraph id="HDCB6C54C10D84239855F26561EA85B17"><enum>(11)</enum><text>We can apply our understanding of NMO to the study of other autoimmune diseases, including multiple sclerosis and systemic lupus erythematosus.</text>
 </paragraph></section><section id="H4A9E29BFD5E24E3AAA63D3BE21F45B34"><enum>3.</enum><header>Sense of Congress</header><text display-inline="no-display-inline">It is the sense of Congress that there is a need—</text> <paragraph id="H03244EA385DC419EAFD9A6061470EA93"><enum>(1)</enum><text>to establish and coordinate a multicenter research effort based on collaboration between regional consortia and governmental and nongovernmental entities in order to—</text>
 <subparagraph id="H331EB5230B4442CCB8BA80D43EBC75DF"><enum>(A)</enum><text>comprehensively study the causes of NMO; and</text> </subparagraph><subparagraph id="H83285AD20FE04788935182268F82DC8B"><enum>(B)</enum><text>identify potential biomarkers of disease activity; and</text>
 </subparagraph></paragraph><paragraph id="HDDEA18748FBC48369055BD4D0B655CD9"><enum>(2)</enum><text>to encourage a collaborative effort among academic medical centers with epidemiological study groups to gather comprehensive and detailed information for each patient enrolled in those groups, in order to investigate environmental, nutritional, and genetic factors with respect to, and the pathological and epidemiological characteristics of, NMO.</text>
 </paragraph></section><section id="H091E60A4F5C54161B39653F753D9C999"><enum>4.</enum><header>Establishment of the National Neu­ro­my­eli­tis Optica Consortium</header><text display-inline="no-display-inline">Part B of title IV of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/284">42 U.S.C. 284</external-xref> et seq.) is amended by adding after section 409J the following new section:</text>
			<quoted-block id="H41D19189B7E54BBBAE3E8861D25F6945" style="OLC">
				<section id="H54F9E882476440CF8C36C4E14FD824F6"><enum>409K.</enum><header>National Neuromyelitis Optica Consortium</header>
					<subsection id="H9CC40427D9B340A09F8B395EED9573B6"><enum>(a)</enum><header>Establishment of the National Neuromyelitis Optica Consortium</header>
 <paragraph id="HA669BF35397140B6A8567C10B35138CD"><enum>(1)</enum><header>In general</header><text>Not later than 1 year after the date of the enactment of this section, the Secretary, acting through the Director of NIH, and in coordination with the Director of the National Institute on Minority Health and Health Disparities, shall establish, administer, and coordinate a National Neuromyelitis Optica Consortium (in this section referred to as the <quote>NNO Consortium</quote>) for the purposes described in paragraph (2).</text>
 </paragraph><paragraph id="HDF6D77D60E3D4B6DA3356F55A4880F39"><enum>(2)</enum><header>Purposes</header><text>The purposes of the NNO Consortium shall be the following:</text> <subparagraph id="HF5BFEB7657664012B4F7CD7931B3BA22"><enum>(A)</enum><text>Providing grants of not fewer than 5 years duration to eligible consortia for the purpose of conducting research with respect to the causes of, and the risk factors and biomarkers associated with, NMO.</text>
 </subparagraph><subparagraph id="H4B7E5A575173416B8F3BA3256FA67C15"><enum>(B)</enum><text>Assembling a panel of experts to provide, with respect to research funded by the NNO Consortium, ongoing guidance and recommendations for the development of the following:</text>
 <clause id="H9392A3B040C443CEB49C36167E2DE71F"><enum>(i)</enum><text>A common study design.</text> </clause><clause id="HF344E1026C78448F93FC4DE9F2F707FB"><enum>(ii)</enum><text>Standard protocols, methods, procedures, and assays for collecting from individuals enrolled as study participants a minimum dataset that includes the following:</text>
 <subclause id="H8E21274FB64D41C09EA97950B6EE128E"><enum>(I)</enum><text>Complete medical history.</text> </subclause><subclause id="H42FFD835B5B44A1E802DACD9B3575B38"><enum>(II)</enum><text>Neurologic examination.</text>
 </subclause><subclause id="H96E8626A3B7E4EA2878907261F95E9E3"><enum>(III)</enum><text>Biospecimens, including blood, spinal fluid, DNA, and RNA.</text> </subclause><subclause id="HBF55F2F59C5A4F4BA86883B9D82C9842"><enum>(IV)</enum><text>Radiological data, including magnetic resonance imaging (MRI).</text>
 </subclause></clause><clause id="HF2525E1131484B61B778A92DE0A18C79"><enum>(iii)</enum><text>Specific analytical methods for examining data.</text> </clause><clause id="H36E71677E1754B64AB74A33968A7D9BE"><enum>(iv)</enum><text>Provisions for consensus review of enrolled cases.</text>
 </clause><clause id="H9EDB0DB7B18D4847B58568DEC362BC6C"><enum>(v)</enum><text>An integrated data collection network.</text> </clause></subparagraph><subparagraph id="HC6B9704757D6463D852C831E0468E5B9"><enum>(C)</enum><text>Designating a central laboratory to collect, analyze, and aggregate data with respect to research funded by the NNO Consortium and to make such data and analysis available to researchers.</text>
 </subparagraph></paragraph><paragraph id="HA5D8CE6D19764EC39C79BE8A1FF05A07"><enum>(3)</enum><header>Eligible consortia</header><text>To be eligible for a grant under this section, a consortium shall demonstrate the following:</text> <subparagraph id="HF24D858F423B4A3397A69FEE0EC3B439"><enum>(A)</enum><text>The consortium has the capability to enroll as research participants a minimum of 25 individuals with a diagnosis of NMO from the consortium’s designated catchment area.</text>
 </subparagraph><subparagraph id="H1FE352334BA54E97A260B619F717D20D"><enum>(B)</enum><text>The designated catchment area of the consortium does not overlap with the designated catchment area of another consortium already receiving a grant under this section.</text>
 </subparagraph></paragraph><paragraph id="H27485941DC0844B4A3EF81CBBCFE788E"><enum>(4)</enum><header>Report</header><text>Not later than 1 year after the date of the enactment of this section, and annually thereafter, the Secretary, acting through the Director of NIH, shall submit to Congress a report with respect to the NNO Consortium, to be made publicly available, including a summary of research funded by the NNO Consortium and a list of consortia receiving grants through the NNO Consortium. At the discretion of the Secretary, such report may be combined with other similar or existing reports.</text>
						</paragraph><paragraph id="H2D7AAE4DD97E441E9C8838719A24A94A"><enum>(5)</enum><header>Authorization of appropriations</header>
 <subparagraph id="HDAD40FD90C2E427088DC31BF34805474"><enum>(A)</enum><header>In general</header><text>There is authorized to be appropriated $25,000,000 for each of fiscal years 2018 through 2021, to remain available until expended, to carry out this section.</text>
 </subparagraph><subparagraph id="HDC47B75BECA1434CADDFA8167BC5487B"><enum>(B)</enum><header>Sense of congress</header><text>It is the sense of Congress that funds appropriated to carry out this section should be in addition to funds otherwise available or appropriated to carry out the activities described in this section.</text>
 </subparagraph></paragraph></subsection><subsection id="H2DED5CC1D51941B5AF305D79B6BA87F9"><enum>(b)</enum><header>Definitions</header><text>For purposes of this section:</text> <paragraph id="HDE8A2BDF495C4B45BF7C0CA672751CBF"><enum>(1)</enum><header>Catchment area</header><text>The term <quote>catchment area</quote> means a defined area for which population data are available.</text>
 </paragraph><paragraph id="H36912B6FE12B453887D8621B0E4A965C"><enum>(2)</enum><header>Consortium</header><text>The term <quote>consortium</quote> means a partnership of two or more universities, health care organizations, or government agencies, or any combination of such entities, serving a designated catchment area.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
		</section></legis-body></bill>


